Cancer Research · 2004 · 606 citations · 13 references
MedicineOncologyPharmacologyBreast OncologyImmunotherapyMolecular OncologyBreast Cancer PharmacotherapyCancer ImmunotherapyHer2-positive Breast CancerTargeted Cancer TherapyTargeted TherapyTyrosine Kinase InhibitorsDrug Combination TherapyHer2 Receptor SignalingHer2 Receptor TargetingHumanized AntibodiesHumanized Monoclonal AntibodiesMitogen-activated Protein Kinase SignalingPertuzumab TherapyReceptor Tyrosine Kinase Activation
Trastuzumab (herceptin) and pertuzumab (Omnitarg, 2C4) are recombinant humanized monoclonal antibodies that target different extracellular regions of the HER-2 tyrosine kinase receptor. We explored combination effects of these agents in the HER-2-overexpressing BT474 breast cancer cell line. Trastuzumab and 2C4 synergistically inhibited the survival of BT474 cells, in part, because of increased apoptosis. Trastuzumab increased 2C4-mediated disruption of HER-2 dimerization with the epidermal growth factor receptor and HER-3. Combination drug treatment reduced levels of total and phosphorylated HER-2 protein and blocked receptor signaling through Akt but did not affect mitogen-activated protein kinase. These results suggest that combining HER-2-targeting agents may be a more effective therapeutic strategy in breast cancer rather than treating with a single HER-2 monoclonal antibody.
13
Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations
Melody Cobleigh, Charles L. Vogel, Debu Tripathy et al. · Journal of Clinical Oncology · 1999 · 2.8K citations
Medicine, Oncology, Pharmacology +17
Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE
Yuri Lazebnik, Scott H. Kaufmann, Serge Desnoyers et al. · Nature · 1994 · 2.6K citations